Show simple item record

dc.contributor.authorJones, RJen_US
dc.contributor.authorHussain, SAen_US
dc.contributor.authorProtheroe, ASen_US
dc.contributor.authorBirtle, Aen_US
dc.contributor.authorChakraborti, Pen_US
dc.contributor.authorHuddart, RAen_US
dc.contributor.authorJagdev, Sen_US
dc.contributor.authorBahl, Aen_US
dc.contributor.authorStockdale, Aen_US
dc.contributor.authorSundar, Sen_US
dc.contributor.authorCrabb, SJen_US
dc.contributor.authorDixon-Hughes, Jen_US
dc.contributor.authorAlexander, Len_US
dc.contributor.authorMorris, Aen_US
dc.contributor.authorKelly, Cen_US
dc.contributor.authorStobo, Jen_US
dc.contributor.authorPaul, Jen_US
dc.contributor.authorPowles, Ten_US
dc.date.accessioned2017-07-05T10:28:34Z
dc.date.issued2017-06en_US
dc.identifier.citationJournal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, 35 (16), pp. 1770 - 1777en_US
dc.identifier.issn0732-183Xen_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/677
dc.identifier.eissn1527-7755en_US
dc.identifier.doi10.1200/jco.2016.70.7828en_US
dc.description.abstractPurpose Two previous single-arm trials have drawn conflicting conclusions regarding the activity of pazopanib in urothelial cancers after failure of platinum-based chemotherapy. Patients and Methods This randomized (1:1) open-label phase II trial compared the efficacy of pazopanib 800 mg orally with paclitaxel (80 mg/m2 days 1, 8, and 15 every 28 days) in the second-line setting. The primary end point was overall survival (OS). Results Between August 2012 and October 2014, 131 patients, out of 140 planned, were randomly assigned. The study was terminated early on the recommendation of the independent data monitoring committee because of futility. Final analysis after the preplanned number of deaths (n = 110) occurred after a median follow-up of 18 months. One hundred fifteen deaths had occurred at the final data extract presented here. Median OS was 8.0 months for paclitaxel (80% CI, 6.9 to 9.7 months) and 4.7 months for pazopanib (80% CI, 4.2 to 6.4 months). The hazard ratio (HR) adjusted for baseline stratification factors was 1.28 (80% CI, 0.99 to 1.67; one-sided P = .89). Median progression-free survival was 4.1 months for paclitaxel (80% CI, 3.0 to 5.6 months) and 3.1 months for pazopanib (80% CI, 2.7 to 4.6 months; HR, 1.09; 80% CI, 0.85 to 1.40; one-sided P = .67). Discontinuations for toxicity occurred in 7.8% and 23.1% for paclitaxel and pazopanib, respectively. Conclusion Pazopanib did not have greater efficacy than paclitaxel in the second-line treatment of urothelial cancers. There was a trend toward superior OS for paclitaxel.en_US
dc.formatPrint-Electronicen_US
dc.format.extent1770 - 1777en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://www.rioxx.net/licenses/all-rights-reserveden_US
dc.subjectHumansen_US
dc.subjectUrologic Neoplasmsen_US
dc.subjectSulfonamidesen_US
dc.subjectPaclitaxelen_US
dc.subjectPyrimidinesen_US
dc.subjectAntineoplastic Agents, Phytogenicen_US
dc.subjectAdministration, Oralen_US
dc.subjectDrug Administration Scheduleen_US
dc.subjectSurvival Rateen_US
dc.subjectAgeden_US
dc.subjectMiddle Ageden_US
dc.subjectFemaleen_US
dc.subjectMaleen_US
dc.subjectKaplan-Meier Estimateen_US
dc.titleRandomized Phase II Study Investigating Pazopanib Versus Weekly Paclitaxel in Relapsed or Progressive Urothelial Cancer.en_US
dc.typeJournal Article
dcterms.dateAccepted2017-04-12en_US
rioxxterms.versionofrecord10.1200/jco.2016.70.7828en_US
rioxxterms.licenseref.urien_US
rioxxterms.licenseref.startdate2017-06en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfJournal of clinical oncology : official journal of the American Society of Clinical Oncologyen_US
pubs.issue16en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Clinical Academic Radiotherapy (Huddart)
pubs.publication-statusPublisheden_US
pubs.volume35en_US
pubs.embargo.termsNot knownen_US
icr.researchteamClinical Academic Radiotherapy (Huddart)en_US
dc.contributor.icrauthorHuddart, Roberten_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record